Glioma clinical trials
Data updated daily from ClinicalTrials.gov, last refresh 2026-11-05
What changed in the last 30 days
88 trials changed in the last 30 days: 3 stopped, 52 with notable changes, 33 with minor changes only.
- Notable: ERP-Based Research on the Modulation of Remimazolam on Working Memory and Brain Network Mechanisms in Glioma Patients Primary endpoint(s) modified
- Notable: / 2 Drug Resistant Immunotherapy With Activated, Gene Modified Allogeneic or Autologous γδ T Cells (DeltEx) in Combination With Maintenance Temozolomide · Recurrent or Newly Diagnosed Glioblastoma Primary and study completion pushed from Dec 2025 to Dec 2026
- Notable: Intracerebral Doses of Neural Stem Cell-Based Virotherapy (NSC-CRAd-S-pk7) · Recurrent High-Grade Gliomas Primary and study completion pushed from Aug 4, 2027 to Feb 7, 2028
- Notable: Intratumoral Extracellular Metabolic Impact of DFMO and AMXT 1501 · Diffuse or High Grade Glioma Primary and study completion dates pushed to Feb 29, 2028
- Notable: PEACH · TRIAL- Precision Medicine and Adoptive Cellular Therapy Enrollment reopened
- Minor: M032-HSV-1 · Genetically Engineered HSV-1 Phase 1 Study · Recurrent Malignant Glioma Trial completed
- Minor: Avutometinib · Solid Tumor Cancers Trial completed
- Stopped: IMED-MYVEO · Image Quality and Safety of the MyVeo Surgical Visualization Headset During Standard Neurosurgical and Reconstructive Procedures Using Compatible Microscopes Withdrawn before enrolling
- Notable: IMED-GLOW400 · Leica Microsystems Sponsored PMCF Study to Collect and Confirm Clinical Data on the Performance of the GLOW400 Device When Used in Accordance With Its Intended Use Recruitment opened
- Notable: Drug Selinexor With Radiation Therapy · Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG) Trial status changed: Suspended → Active, Not Recruiting
- Notable: LWBC · Living Well With Brain Cancer: A Group-Based Intervention to Promote Whole-Person Well-Being Recruitment opened
- Minor: Chemoradiotherapy Versus Chemotherapy for Elderly and Frail GBM Patients Enrollment closed, study ongoing
- Minor: Addition of an Anti-cancer Drug, Vorasidenib to Temozolomide, After Radiation for Advanced Brain Cancer Trial sites expanded: 152 → 177 locations
- Stopped: XPedite: A Study to Expedite DIPG and DMG Research Trial status changed: Recruiting → Withdrawn
- Notable: Autologous Natural Killer Cell Therapy (CHANK-101) · Recurrent Glioblastoma Start date pushed from Sep 29, 2026 to Nov 29, 2026
- Minor: PNOC016 · Fimepinostat in Treating Brain Tumors in Children and Young Adults Trial completed
- Minor: ADAGiO · Adoptive Cellular Therapy · Recurrent OliGodendrogliOma (OG) Adult Patients Enrollment closed, study ongoing
- Minor: Silevertinib With Temozolomide · Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII Trial sites expanded: 34 → 38 locations
- Minor: Pediatric Trial of Indoximod With Chemotherapy and Radiation for Relapsed Brain Tumors or Newly Diagnosed DIPG Study completion pushed from Oct 2, 2027 to Dec 11, 2027
- Minor: Chemo-immunotherapy Using Ibrutinib Plus Indoximod · Pediatric Brain Cancer Study completion pushed from Sep 30, 2028 to Dec 28, 2029
- Stopped: terminated, suspended or withdrawn
- Notable: the plan changed
- Minor: routine updates
New sponsor entrants, last 90 days sponsors with their first trial in this area
| First posted | Trial | Sponsor | Phase |
|---|---|---|---|
| 2026-11-02 | NCT07909811 Novel endOvascular Therapy With beVAcizumab and Cannabinoids for Glioblastoma | Unity Health Toronto new | Phase 1 |
| 2026-10-28 | NCT07902037 A Study of SRN-101 Gene Therapy in Adults With Recurrent High-Grade Glioma (ALERT-1) | Siren Biotechnology new | Phase 1/2 |
| 2026-10-09 | NCT07869524 IMPT Versus IMRT for Diffuse Intrinsic Pontine Glioma | Shandong Cancer Hospital and Institute new | Phase 3 |
| 2026-09-22 | NCT07832448 Microsurgical Resection Combined With Photodynamic Therapy for Recurrent Glioblastoma | Yonggao Mou new | |
| 2026-09-21 | NCT07831369 VISTA: Valproic Acid, Irinotecan, and Simvastatin for Recurrent Glioma | Inova Health Care Services new | Phase 2 |
| 2026-09-11 | NCT07814872 A Preregistered Multi-Cohort Evaluation of the FATHOM AI System for Molecular Testing… | Harvard Medical School (HMS and HSDM) new | |
| 2026-09-10 | NCT07813377 Usefulness of Thromboelastography as a Predictor of Prognosis in Patients Undergoing… | Fundacion Clinic per a la Recerca Biomédica new | |
| 2026-09-09 | NCT07809178 China Treatment Trial for Tumor in Sellar Region With Unruptured Intracranial Aneurysm | Cheng sen new | |
| 2026-08-27 | NCT07789678 Epidemiological Profile of Patients With IDH-Mutant Diffuse Gliomas Diagnosed From 2021… | Latin American Cooperative Oncology Group new | |
| 2026-08-26 | NCT07788677 Tarlatamab Treatment Before and After Surgery in Surgically Resectable Recurrent… | Vall d'Hebron Institute of Oncology new | Phase 1 |
Active trials by phase
| Early Phase 1 | 68 | |
| Phase 1 | 212 | |
| Phase 1/2 | 120 | |
| Phase 2 | 217 | |
| Phase 2/3 | 15 | |
| Phase 3 | 53 | |
| Phase 4 | 9 |
Not charted: 348 active trials with no phase listed on ClinicalTrials.gov (typically behavioural, device, procedure and observational studies).
Top sponsors by active trials in this area
National Cancer Institute (NCI) (37) · M.D. Anderson Cancer Center (23) · Mayo Clinic (23) · Beijing Tiantan Hospital (14) · Memorial Sloan Kettering Cancer Center (14) · University of Florida (13) · City of Hope Medical Center (12) · Nationwide Children's Hospital (12) · St. Jude Children's Research Hospital (12) · Washington University School of Medicine (11)
Get alerts when Glioma trials change
Status changes, date slips, and new sponsor entrants: detected daily, delivered to your inbox.